Navigation Links
Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
Date:10/29/2007

bility to successfully complete the implementation of a company-wide enterprise resource planning system without disrupting our business; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing and marketing new products, obtain regulatory approval and customer acceptance of those products, and continued customer acceptance of our existing products; and other risks detailed from time-to-time in our periodic reports filed with the Securities and Exchange Commission, our financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceutical's Web site at http://www.watson.com.

Watson's Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Ac
'/>"/>

SOURCE Warner Chilcott Company, Inc.; Watson Pharmaceuticals,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Charter and Time Warner to partner on fiber optics
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Speaker announces business members of IT Task Force
5. Doyle announces technology tax credits for Berbee
6. Doyle announces new energy, global warming policies
7. Doyle, WARF announce partnership to lure stem cell companies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 Shire plc (LSE: ... specialty biopharmaceutical company, and ArmaGen, a US privately ... and collaboration agreement for AGT-182, an investigational enzyme ... both the central nervous system (CNS) and somatic ... This collaboration strengthens Shire,s rare disease pipeline of ...
(Date:7/23/2014)... -- GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical cannabis research and ... medical marijuana dispensary locations in Las Vegas, Nevada ... Clark County, Nevada dispensary for which the ... GrowBLOX Sciences, CEO Craig Ellins stated, ... dispensaries in the City of Las Vegas ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
(Date:7/23/2014)... , July 23, 2014 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... Group Limited ("Cordlife"), a multi-product healthcare company catering to the mother ... forces in assisting patients across the PRC, Singapore ... , India , the Philippines ...
Breaking Biology Technology:Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3Sofinnova Raises $500 Million Biotech Venture Fund 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... Up 14 Percent over Third Quarter 2007 ... Earnings Guidance, Introduces 2009 Adjusted Net Income Guidance, ... Cephalon, Inc. (Nasdaq:,CEPH) today reported third quarter 2008 sales ... third quarter of 2007, and at the high,end of the ...
... NVAX ) a clinical-stage vaccine company, announced today ... be presenting at,the BIO Investor Forum 2008 at 8:30 ... in San Francisco, California. Dr. Singhvi will provide an,overview ... to the live presentation can be accessed via the ...
... Antibiotics Ltd., the,developer of novel polymyxin derivatives ... Gram-negative bacteria, revealed today animal,efficacy and pharmacokinetic ... 48th,Annual ICAAC/IDSA 46th Annual Meeting in Washington, ... series of novel polymyxin (NAB),compounds (Vaara M. ...
Cached Biology Technology:Cephalon Reports Another Strong Quarter 2Cephalon Reports Another Strong Quarter 3Cephalon Reports Another Strong Quarter 4Cephalon Reports Another Strong Quarter 5Cephalon Reports Another Strong Quarter 6Cephalon Reports Another Strong Quarter 7Cephalon Reports Another Strong Quarter 8Cephalon Reports Another Strong Quarter 9Cephalon Reports Another Strong Quarter 10Cephalon Reports Another Strong Quarter 11Cephalon Reports Another Strong Quarter 12Cephalon Reports Another Strong Quarter 13Cephalon Reports Another Strong Quarter 14Cephalon Reports Another Strong Quarter 15Cephalon Reports Another Strong Quarter 16Cephalon Reports Another Strong Quarter 17Cephalon Reports Another Strong Quarter 18Cephalon Reports Another Strong Quarter 19Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008 2Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008 3
(Date:7/23/2014)... emulsions are crucial for providing essential fatty acids ... intravenous feeding. There has been concern that soybean-based ... damage due to its composition. Combination lipid emulsions ... oil have been developed to address this concern. ... found that concern may be unwarranted, according to ...
(Date:7/22/2014)... both still images and video of artistic merit ... still images were chosen from more than 250 ... alumni representing more than 25 different University departments. ... submissions. , Zach Donnell, a graduate student in ... noted that the exhibit highlights the interplay between ...
(Date:7/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2014. Revenue for the ... 53% compared to $4.4 million in the same quarter last ... quarter of 2014 was $1.4 million compared to $0.5 million ... and operating income was driven by higher sales of software ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... a new door to developing drugs to slow the ... Edward A. Fon at the Montreal Neurological Institute and ... in the Department of Biochemistry at the Faculty of ... Parkin. Mutations in Parkin cause a rare hereditary form ...
... around and often organize into highly resilient communities known as ... pattern similar to many economies, according to a new study ... Washington. The study, published online May 8 in ... the strategy by which bacteria form the micro-colonies that become ...
... the Southern Appalachian region of the United States could ... study by U.S. Forest Service scientists at the Coweeta ... online in the journal Ecological Applications and ... woolly adelgid, an exotic invasive insect, has caused widespread ...
Cached Biology News:Unleashing the watchdog protein 2Study finds that bacteria organize according to 'rich-get-richer' principle 2Study finds that bacteria organize according to 'rich-get-richer' principle 3Loss of eastern hemlock will affect forest water use 2
...
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: